Compare Tsumura & Co. with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 77.56
2
Low Debt Company with Strong Long Term Fundamental Strength
3
The company has declared Positive results for the last 4 consecutive quarters
4
With ROE of 11.50%, it has a very attractive valuation with a 0.85 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 319,085 Million (Mid Cap)
7.00
NA
0.00%
0.14
9.90%
1.09
Revenue and Profits:
Net Sales:
55,279 Million
(Quarterly Results - Dec 2025)
Net Profit:
11,177 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.89%
0%
-7.89%
6 Months
1.85%
0%
1.85%
1 Year
-14.12%
0%
-14.12%
2 Years
-5.1%
0%
-5.1%
3 Years
45.72%
0%
45.72%
4 Years
12.64%
0%
12.64%
5 Years
-1.91%
0%
-1.91%
Tsumura & Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.00%
EBIT Growth (5y)
16.28%
EBIT to Interest (avg)
77.56
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.45
Tax Ratio
24.22%
Dividend Payout Ratio
31.84%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
9.80%
ROE (avg)
8.00%
Valuation key factors
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
0.85
EV to EBIT
6.31
EV to EBITDA
4.94
EV to Capital Employed
0.85
EV to Sales
1.40
PEG Ratio
0.08
Dividend Yield
0.01%
ROCE (Latest)
13.48%
ROE (Latest)
11.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot : Jun 2020
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
55,279.00
47,702.00
15.88%
Operating Profit (PBDIT) excl Other Income
15,188.00
14,044.00
8.15%
Interest
273.00
125.00
118.40%
Exceptional Items
0.00
-32.00
100.00%
Consolidate Net Profit
11,177.00
9,470.00
18.03%
Operating Profit Margin (Excl OI)
212.40%
237.00%
-2.46%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 15.88% vs 17.71% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 18.03% vs 16.42% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
181,093.00
150,845.00
20.05%
Operating Profit (PBDIT) excl Other Income
51,296.00
30,772.00
66.70%
Interest
518.00
330.00
56.97%
Exceptional Items
-32.00
0.00
Consolidate Net Profit
34,523.00
18,046.00
91.31%
Operating Profit Margin (Excl OI)
221.60%
132.70%
8.89%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 20.05% vs 7.71% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 91.31% vs 3.80% in Mar 2024
About Tsumura & Co. 
Tsumura & Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






